Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
At last week's HIV Research for Prevention (HIVR4P) conference in Madrid, scientists reported progress in numerous areas of HIV prevention research.
Several presentations at the 2018 HIV Research for Prevention conference looked at the new challenges of evaluating efficacy of new PrEP and vaccine candidates.
There are a number of measures determine adherence to PrEP, each with benefits and drawbacks. Currently, no one guideline or definitive standard is being used.
Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.
When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference?
The CDC has released new data at the Conference on Retroviruses and Opportunistic Infections (CROI) estimating that only a small percentage of people most at risk for HIV infection have actually been prescribed pre-exposure prophylaxis (PrEP).
In New York City, the number of people taking PrEP has skyrocketed in recent years -- yet prescriptions are more likely to be written for affluent white men than others, research finds.